Suppr超能文献

用于比较随机化 II 期研究中二项分布比例的实用且稳健的检验方法。

Practical and robust test for comparing binomial proportions in the randomized phase II setting.

机构信息

Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

Department of Biostatistics, University at Buffalo, Buffalo, New York, USA.

出版信息

Pharm Stat. 2022 Mar;21(2):361-371. doi: 10.1002/pst.2174. Epub 2021 Oct 9.

Abstract

The one-arm, non-randomized, one/two-stage phase II designs have been a mainstay in oncology trials for evaluating response rates or similar variants (i.e., tests about single proportions). With the goal of screening new therapies that have the potential to move into a randomized phase III trial or a subsequent randomized phase II trial, all while maintaining a logistically feasible sample size. However, since the implementation of the Food and Drug Administration's Fast Track Designation, there has been a trend toward randomized phase II clinical trials as a source of stronger evidence for those seeking fast-track approvals. While there are many single- and multi-stage randomized designs for evaluating proportions in this phase II setting, there still exist limitations in terms of sample size (which directly impacts cost and study duration) or operating characteristics (ex. maintained type I error). In this article, we propose a new test for comparing two binomial proportions, which is a modification across existing methods (the standard z-test and Jung's test). This approach is contrasted with existing methods via numeric evaluation and further contrasted using a real-world oncology trial. The proposed method demonstrates improvements in efficiency and robustness against deviations from design assumptions. When applied to the existing trial, significant savings with respect to cost and time are illustrated. Our proposed test for comparing binomial proportions provides an efficient and robust alternative in the randomized phase II oncology setting, especially when the control arm has a high rate.

摘要

单臂、非随机、一/两阶段的 II 期设计一直是肿瘤学试验中评估反应率或类似变体(即关于单一比例的检验)的主要方法。其目的是筛选有可能进入随机 III 期试验或后续随机 II 期试验的新疗法,同时保持可行的样本量。然而,自从食品和药物管理局的快速通道指定实施以来,随机 II 期临床试验已成为寻求快速通道批准的人获得更强有力证据的趋势。虽然在这种 II 期环境中,有许多用于评估比例的单阶段和多阶段随机设计,但在样本量方面仍然存在局限性(直接影响成本和研究持续时间)或操作特性(例如,保持 I 类错误)。在本文中,我们提出了一种用于比较两个二项式比例的新检验方法,这是对现有方法(标准 z 检验和 Jung 检验)的修改。通过数值评估和使用真实肿瘤学试验进一步对比,这种方法与现有方法形成了对比。所提出的方法在效率和对设计假设偏离的稳健性方面表现出了改进。当应用于现有试验时,说明了在成本和时间方面的显著节省。我们提出的用于比较二项式比例的检验方法为随机 II 期肿瘤学环境提供了一种高效且稳健的替代方法,特别是在对照臂具有高比率的情况下。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b45/9539861/31d3dee11406/PST-21-361-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验